Expert Opinion on Drug Safety · 2014 · 55 citations · 27 references
PharmacyPediatricsPharmacologyClinical PharmacologyPediatric EpidemiologyPharmacovigilanceAdverse Drug Event ReportingAdverse Drug Reaction MonitoringAdverse Drug Reaction ReportingAdverse Drug ReactionsDrug Safety MonitoringPediatric Adverse Drug ReactionsActive PharmacovigilanceAdverse Drug Reaction AnalysisAdverse Drug Reaction SurveillanceDrug Monitoring In PediatricsPediatric Adverse Drug Reaction ReportingPediatric Adverse Reaction MonitoringPediatric Safety SurveillanceSerious Adverse Drug Reactions
OBJECTIVE: To gain information on safety of drugs used in pediatrics through a 4-year post-marketing active pharmacovigilance program. The program sampled the Italian population and was termed 'Monitoring of the Adverse Effects in Pediatric population' (MEAP). RESEARCH DESIGN AND METHODS: Adverse drug reactions (ADRs) were collected for individuals aged 0 - 17 years treated in hospitals and territorial health services in Lombardy, Tuscany, Apulia and Campania; located to gain an appropriate sampling of the population. ADRs were evaluated using the Adverse Drug Reaction Probability Scale (Naranjo) and analyzed with respect to time, age, sex, category of ADR, seriousness, suspected medicines, type of reporter and off-label use. RESULTS: We collected and analyzed reports from 3539 ADRs. Vaccines, antineoplastic and psychotropic drugs were the most frequently pharmacotherapeutic subgroups involved. Seventeen percent of reported ADRs were serious; of them fever, vomiting and angioedema were the most frequently reported. Eight percent of ADRs were associated with off-label use, and 10% were unknown ADRs. Analysis of these revealed possible strategies of therapy optimization. CONCLUSIONS: The MEAP project demonstrated that active post-marketing pharmacovigilance programs are a valid strategy to increase awareness on pediatric pharmacology, reduce underreporting and provide information on drug actions in pediatrics. This information enhances drug therapy optimization in the pediatric patients.
27
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
The Impact of Unlicensed and Off-Label Drug Use on Adverse Drug Reactions in Paediatric Patients
Antje Neubert, Harald Dormann, Jutta Weiss et al. · Drug Safety · 2004 · 194 citations
Pharmacy, Pediatrics, Pharmacology +15
Suspected Adverse Drug Reactions Reported For Children Worldwide
Kristina Star, G. Niklas Norén, Karin Nordin et al. · Drug Safety · 2011 · 115 citations
Pharmacy, Pediatrics, Pharmacology +13